Marianne Boutin

Montreal, QC H3C3J7, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV.

Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV.

Journal: Viruses
Published: August 22, 2023

Temsavir Modulates HIV-1 Envelope Conformation by Decreasing Its Proteolytic Cleavage.

Temsavir Modulates HIV-1 Envelope Conformation by Decreasing Its Proteolytic Cleavage.

Journal: Viruses
Published: March 28, 2023

Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120.

Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120.

Journal: Cell chemical biology
Published: October 14, 2022

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile.

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile.

Journal: Cell reports. Medicine
Published: August 08, 2022

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies.

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies.

Journal: mBio
Published: April 27, 2022

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.

Journal: Cell reports
Published: April 18, 2022

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.

Journal: Cell reports
Published: December 21, 2021

B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders.

B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders.

Journal: Vaccine
Published: December 17, 2021

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality.

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality.

Journal: Science advances
Published: November 26, 2021

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.

Journal: Cell host & microbe
Published: September 13, 2021

Identification of SARS-CoV-2-specific immune alterations in acutely ill patients.

Identification of SARS-CoV-2-specific immune alterations in acutely ill patients.

Journal: The Journal of clinical investigation
Published: November 17, 2020
Showing 1-11 of 11

Last Updated: 09/26/2026